These results demonstrate the ability of TRPV1 blockade-synergized thermo-immunotherapy to elicit robust immune responses, thus accounting for preferable therapeutic efficacy against large pancreatic tumor models. The gene discussed is TRPV1; the disease is pancreatic neoplasm.